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Abstract Tumor necrosis factor (TNF) is a growth-modulatory cytokine that inhibits the growth of certain cell lines, stimulates the growth of some, 
and has no effect on the growth of still others. The molecular basis for this differential regulation of growth by TNF is not understood. We postulate 
that the growth of normal or tumor cells is determined by the balance between growth-stimulatory and -inhibitory signals. In the present study, we 
demonstrate that the transfection of cells with the transforming growth factor (TGFJ-cz gene induces resistance to TNF. Colon carcinoma cell lines 
that express elevated levels of TGF-a were also found to be resistant o this cytokine. Exogenous addition of the growth factor was also effective 
in decreasing the antiproliferative ffects of TNF. Transfection of cells with the TGF-a gene led to downmodulation of TNF receptors but an increase 
in intracellular glutathione levels. Thus, these results support our hypothesis that expression of growth factors by certain tumor cells can lead to 
resistance to antiproliferative agents such as TNF. 
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1. Introduction 
Tumor necrosis factor (TNF) is a highly pleiotropic cytokine 
with both a transmembrane and secreted form of 213 and 157 
amino acid residues, respectively [1,2]. Depending on the cell 
line, it has differential growth-modulatory effects, inhibiting the 
growth of some while stimulating that of others in culture [3]. 
While several cell lines are highly sensitive to the effects of 
TNF, others are quite resistant. The molecular basis for this 
resistance is not understood but roles for manganese superox- 
ide dismutase, growth factors, pp60““‘, HER2/neu/erb B2, and 
glutathione have been demonstrated [4-81. Interestingly, the 
expression of TNF itself by certain tumor cells has been shown 
to cause resistance to TNF [9]. 
Transforming growth factor-a (TGF-a) is a potent mitogen 
that is synthesized as a 160 amino acid glycosylated and palmi- 
toylated transmembrane precursor. It is released from the cell 
surface by proteolysis (between alanine and valine) of the ex- 
tracellular domain as a 50-amino acid mature peptide (for ref- 
erences ee [lo]). Like TNF, the transmembrane (unprocessed) 
form of TGF-a can transduce signals. TGF-a is a member of 
the epidermal growth factor (EGF) family of proteins, and it 
shares structural and functional characteristics with EGF. 
TGF-a also binds to the EGF receptor that is a protein tyrosine 
kinase. Elevated levels of TGF-a have been associated with 
cellular transformation [l 1,121, and functioning as an autocrine 
growth factor in human renal cell carcinoma, colon carcinoma, 
breast adenocarcinoma, pancreatic carcinoma, and prostatic 
carcinoma [13-191. Overexpression of this cytokine in trans- 
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genie mice has been shown to cause epithelial hyperplasia, 
pancreatic metaplasia, and carcinoma of the breast [20]. 
The differential growth-modulatory activities of TNF 
against different cell types may be the result of differences in 
the balance between growth-stimulatory and -inhibitory sig- 
nals. Previously, we have shown that cells transfected with the 
human protein tyrosine kinase genes EGF receptor-2 (HER-21 
erb Blneu), or with pp60”+” are resistant to TNF [6,7]. In the 
present study, we investigated the effects of TGF-a transfection 
on the anticellular activity of TNF. We found that it also 
induced resistance to TNF. In contrast to ~~60’.“’ but like Her2 
kinase, resistance induced by TGF-a was accompanied by the 
modulation of TNF receptors. Cellular resistance to TNF cor- 
related with an increase in intracellular glutathione levels. 
2. Materials and methods 
2.1. Materials 
Gentamicin and fetal calf serum (FCS) were obtained from GIBCO, 
Grand Island, NY. DMEM was obtained from Whittaker MA Bio- 
products, Walkersville, MD. Bacteria-derived recombinant human 
TNF and murine interferon-y (IFN-y) purified to homogeneity were 
kindly provided by Genentech Inc., South San Francisco, CA. Other 
chemical agents were purchased from Sigma Chemical Company (St. 
Louis, MO). 
2.2. Cells 
Human colon carcinoma cell lines, HCT116 and JVC which secrete 
elevated levels of TGF-a protein [14], were kindly provided by Dr. S. 
Chakrabarty from M.D. Anderson Cancer Center, Houston. Human 
TGF-a-transfected NIH3T3 cells and the neomycin (neo)-transfected 
control lines were the gift of Dr. Stuart A. Aaronson of the National 
Cancer Institute, Bethesda, MD. Cells were transfected with plasmid 
pSVTGFa containing a 595-bp fragment comprising the entire coding 
region for TGF-u but lacking a potential polyadenylation signal [12]. 
Cells were routinely grown in DMEM supplemented with glutamine (2 
mM), gentamicin (50 &ml), and FBS (10%) in a humidified incubator 
in 5% CO* in air. Occasionally, the transfected cells were checked for 
neomycin resistance by including G418 (500 pg/ml) in the medium. 
2.3. Antiproliferation assays 
For growth inhibition assays, cells (5 x lO’/well) were plated over- 
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Fig. 1. Antiproliferative effects of different concentrations of TNF 
against neo and TGF-a-transfected NIH3T3 cells. 5 x 10’ cells/well in 
0.1 ml were incubated with various concentrations of human TNF in 
96-well plates at 37°C for 72 h. The relative cell viability was deter- 
mined by staining with Crystal violet as described in section 2. All 
determinations were in triplicate. 
night in 0.1 ml of DMEM with 10% FBS in 96-well Falcon plates. 
Thereafter, the medium was removed and a serial dilution of human 
TNF was layered in 0.1 ml of the medium. After a 72-h incubation at 
37”C, the viable cells were monitored by crystal violet staining accord- 
ing to the procedure as described [3]. The relative cell viability was 
calculated as optical density in the presence of the test sample divided 
by optical density in the absence of the test sample (medium) and 
expressed as a percentage. 
2.4. Receptor-binding assay 
Binding assays were performed in96-well microplates (Falcon 3911, 
Becton Dickinson Labware, Oxnard, CA) as described [21,22]. 
2.5. Determination of intracellular glutathione l vels 
The intracellular glutathione levels were determined by ion-exchange 
high-performance liquid chromatography as described previously [23]. 
Briefly, 3 x lo6 cells were homogenized in 10% HClO, and centrifuged. 
The pellet was analyzed for protein by the method of Lowry, and the 
supematant was analyzed for glutathione content. All determinations 
were made in triplicate, and the results were expressed as nanomoles 
of glutathione per mg of protein. 
whereas TGF-a-transfected cells were relatively resistant. At 20 
ng/ml TNF, the growth inhibition of control and TGF-a-trans- 
fected cells was 78% and 5%, respectively. 
Since TGF-a-transfected cells grow faster than control cells, 
we also examined the effect of TNF on the growth rate of cells 
as determined by the change in viable cell number over time. 
The results of this experiment, shown in Fig. 2, indicated that 
in the presence of TNF the growth of control cells was inhibited 
by almost 3-fold for up to 6 days (upper panel), whereas TGF- 
a-transfected cells continued to proliferate in the presence of 
TNF at a rate identical to untreated cells (lower panel). These 
results further confirm the role of TGF-a transfection in induc- 
ing resistance to TNF. NIH-3T3 cells transfected with the 




3.1. NIH-3T3 cells transfected with TGF-a are resistant o TNF 
First we examined the antiproliferative effects of TNF by 
crystal violet dye uptake on NIH3T3 cells transfected with 
either the neo (control) or TGF-a gene. The control cells were 
growth inhibited by TNF in a dose-dependent manner (Fig. I), 
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Fig. 2. Effect of TNF on the growth rate of neo- (upper panel) and 
TGF-a-transfected (lower panel) NIH3T3 cells. 5 x 10’ cells/well in 1 
ml were incubated in the presence or absence of TNF (20 @ml) in 
24-well plates at 37’C. At indicated times cell number was determined 
by the Trypan blue exclusion method as described in section 2. All 
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Fig. 3. Effect of TNF on the morphology of neo control and TGF-a-transfeeted NIH3T3 cells. 5 x 10’ cells/well in 1 ml were incubated in the presence 
or absence of TNF (20 rig/ml) in 24-well plates at 37°C for 72 h, the media changed, and the cells photographed at 32x magnification. 
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TGF-a gene were also examined for morphology. As shown in 
Fig. 3, cells transfected with TGF-a differed significantly in 
morphology from that of neo control. Control cells had a flat- 
tish whereas TGF-a-transfected cells were spindle shaped. 
3.2. Tumor cell lines that overexpress TGF-a are resistant o 
TNF 
Human colon carcinoma cell lines HCT116 and JVC have 
been shown to secrete elevated levels of TGF-a (5.7 +_ 2.2 and 
9.4 + 0.5 r&ml) [14]. To corroborate our observation on TGF- 
a-transfected cells, we examined these cell lines for sensitivity 
to TNF. As shown in Fig. 4, both cell lines were as resistant 
to TNF as TGF-a transfected cells. 
3.3. Exogenous addition of EGF reduces the sensitivity of cells 
to TNF 
TGF-a and EGF are structurally and functionally homolo- 
gous proteins that interact with a common cell surface receptor 
[lo]. To determine if exogenous addition of EGF could reduce 
the sensitivity of cells to TNF, neo control cells were exposed 
to TNF in the presence and absence of EGF. As shown in Fig. 
t 
Fig. 4. Effect of TNF on the viability of neo- and TGF-a-overexpressing 
cell lines. 5 x lo3 cells/well in 1 ml were incubated in the presence or 
absence of TNF (200 @ml) in 96-well plates at 37°C for 72 h and then 
cell viability was determined by the Crystal violet method as described 
in section 2. All determinations were in duplicate. 
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Fig. 5. Effect of exogenous epidermal growth factor on the antiprolifer- 
ative effects of TNF against neo NIH3T3 cells. 5 x 10’ cells/well in 0.1 
ml were incubated with either human TNF (2 q/ml) or TNF and EGF 
(10 @ml) in 96-well plates at 37°C for 72 h. The relative cell viability 
was determined by staining with crystal violet as described in section 
2. All determinations were in triplicate. 
5, EGF treatment significantly decreased the antiproliferative 
effect of TNF. These results are consistent with those obtained 
with TGF-a-transfected cells. 
3.4. Cellular resistance to TNF by TGF-a-transfection down 
modulates TNF receptors 
Previously we have shown that transfection of cells with the 
HER2 oncogene leads to a resistance of cells to TNF that 
correlates with down modulation of TNF receptors [7]. There- 
fore, we examined the effect of TGF-a transfection of cells on 
TNF receptors. The results shown in Fig. 6 indicate that there 
was a significant decrease in the binding of TNF to TGF-a- 
transfected cells as compared to the neo control. 
3.5. Cellular resistance to TNF induced by TGF-a correlates 
with an increase in intracellular glutathione levels 
We have reported that the cell density-dependent [24] cellular 
resistance to TNF and that induced by pp60’~“” [6] correlate 
with the decrease in intracellular glutathione levels. We, there- 
fore, examined glutathione levels in control and TGF-a-trans- 
fected cells. There was about 80% more glutathione in the 
TGF-a-transfected cells than in the neo control (Fig. 7). 
4. Discussion 
We report here that transfection of NIH-3T3 cells with TGF- 
a leads to resistance to the antiproliferative ffects of TNF. The 
induction of resistance was accompanied by modulation of 
TNF receptors and an increase in intracellular glutathione lev- 
els. 
Why some tumor cells are sensitive and others resistant to 
TNF is not understood. Previously, we have shown that tumor 
cells overexpressing HER2 or pp60’“” are resistant to TNF 
[6,7]. We now report that TGF-a overexpression also induces 
TNF resistance and that this may occur through the modula- 
tion of TNF receptors, as was the case for HER2. TGF-a 
mRNA is overexpressed in several different types of tumors 
and tumor cell lines, including glioblastomas, fibrosarcoma, 
colon carcinoma, pancreatic carcinoma, prostate carcinoma, 
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Fig. 6. Specific binding of labeled hTNF to control and TGF-a-trans- 
fected NIH3T3 cells. 1 x lo6 cells (0.1 ml) in 96-well plates were incu- 
bated with different concentrations of labeled TNF either in the 
presence (nonspecific binding) or absence (total binding) of 100 nM 
unlabeled TNF for 1 h at 4°C. Thereafter cells were centrifuged and 
washed thrice, and cell-bound radioactivity counted. Specific binding 
was calculated as a difference between total binding and nonspecific 
binding. All determinations were made in triplicate. 
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Fig. 7. Intracellular glutathione levels in control and TGF-a-trans- 
fected NIH3T3 cells. Bars represent he glutathione levels (nmoles per 
mg of protein) in neo and TGF-a-transfected NIH3T3 cells. All determi- 
nations were made in triplicate. 
and breast carcinoma [13-191. Human tumor cell lines HCT 116 
and JVC (colon adenocarcinoma), which are known to overex- 
press TGF-a [14], were also found to be resistant to TNF. 
How TGF-a induces resistance to TNF is not clear. It has 
been shown, however, that TNF causes the induction of TGF- 
cllEGF receptors and promotes the autophosphorylation of the 
EGF receptor in certain cell lines [25,26]. Recently we have 
shown that protein tyrosine phosphatases play an important 
role in TNF-mediated antiproliferative effects [27]. Since the 
proliferative effects of TGF-a are mediated through protein 
phosphorylation whereas the antiproliferative effects of TNF 
appear to be mediated through dephosphorylation, it is possi- 
ble that TGF-a inactivates the protein tyrosine phosphatase 
pathway resulting in cellular resistance. Unlike the studies on 
the effect of pp60’“” [6], we found that resistance of TGF-a- 
transfected cells to TNF cannot be overcome by treatment of 
cells with IFN-y (data not shown). We also found that TGF-a- 
mediated cellular resistance leads to an increase in intracellular 
glutathione levels. This result is inconsistent with our recent 
report showing an association between cell-density-dependent 
resistance to TNF and a decrease in intracellular GSH levels 
[24]. A decrease of GSH was also observed in cells transfected 
with pp60”+” [6]. The results are, however, consistent with ele- 
vation of intracellular GSH levels that occurs in tumor cells 
which develop resistance to chemotherapeutic agents [23,28]. 
Since turnorigenesis is a result of the altered expression of 
multiple oncogenes and growth factors, it is possible that differ- 
ent mechanisms in different tumor cells contribute to the induc- 
tion of resistance to TNF. 
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